Risk Management for Aseptic Processing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Risk Management for Aseptic Processing
The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.

Pharmaceutical Technology

Implications of risk assessment on processing

Table III: 3-D risk assessment for purified water system.
When a process step or other activity is determined to be high risk, what should be done? These determinations should cause initiation of project activities to reduce the risk level. However, if reduction is not possible, there should be additional in-process controls, additional testing, additional training, and so on. In summary, the organization should expend additional effort to mitigate or control the risk situation. At the same time, efforts on processes or activities that are well controlled or do not represent risk can be minimized. For example, a new purified water (PW) supply was planned for an aseptic processing facility. This PW supply was to be used as feed water for a water-for-injection (WFI) still, for initial rinse water for clean in place (CIP) of formulation and filling equipment, and for make-up of wash solutions for CIP of formulation and filling equipment. WFI was used for the final rinse of this equipment. Based on these parameters, a 3-D risk assessment was performed on the PW system, giving the results shown in Table III.

The overall score determined by this risk assessment is 30, indicating the overall risk is low to medium. This low overall score indicates that detailed formal risk assessment methods such as FMEA are not needed for this system. While the overall risk score indicates few controls are needed, the distance along product stream score indicates that some engineering controls and in-process controls are justified. Based on this analysis, the design engineer decides to add an ultraviolet (UV) system for controlling bioburden, as well as conductivity alarms to indicate system problems. In addition, periodic monitoring and trending of system bioburden is justified.

Table IV: 3-D risk assessment for aseptic filler.
A contrasting example would be an aseptic filler intended for multiproduct use. This filler is designed for high-speed filling and stoppering of several different products with rapid changeover. This filler is designed for in-line check weighing, and for automated CIP and sterilization in place (SIP). A 3-D risk assessment of this equipment gave the results shown in Table IV.

Table V: Process FMEA example (system=aseptic filler; process=clean-in-place).
The risk assessment clearly indicates the filler is a high risk system. Based on this assessment, design and process FMEAs were performed on the filler to identify controls to mitigate high-risk items. Table V is a partial example of a process FMEA used to identify design controls for the new filler.

This example shows a small portion of a detailed FMEA for the CIP process for a critical system (aseptic filler). A FMEA such as this one could be used to put additional controls into place during design of the system, as well as to identify critical items that need to be verified during validation.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here